Health

Moderna Hits Key Enrollment Milestone in Vaccine Trial, On Track for December Debut

Moderna has finished enrolling all 30,000 of the participants in its U.S. clinical trials for a coronavirus vaccine, putting the company on pace to have a public-ready product by December, the drugmaker announced Thursday.

All trial participants have received their first shot, with most also receiving the required second shot, CNN reported.

Dr. Stephen Hoge, the company president, said Moderna will apply for authorization from the Food and Drug Administration to enter the marketplace in early December “if all the stars align,” CNN reported.

Moderna, one of four companies currently conducting Phase 3 trials of coronavirus vaccines in the U.S., was the first to begin, starting its trial on July 27. AstraZeneca, Pfizer and Johnson & Johnson are the other companies, with Pfizer the furthest along of the three.

As of Thursday afternoon, the U.S. has approximately 8.4 million coronavirus cases and 223,000 related deaths — both tops globally — according to a Johns Hopkins University tracker.

Tags
Show More

Related Articles

Leave a Reply

Your email address will not be published. Required fields are marked *


By submitting this form, you are consenting to receive marketing emails from: Washington Informer Newspaper, 3117 Martin Luther King Jr. Ave SE, Washington, DC, 20032, http://www.washingtoninformer.com. You can revoke your consent to receive emails at any time by using the SafeUnsubscribe® link, found at the bottom of every email. Emails are serviced by Constant Contact

Back to top button

My News Matters to me - Washington Informer Donations

Be a Part of The Washington Informer Legacy

A donation of your choice empowers our journalists to continue the work to better inform, educate and empower you through technology and resources that you use.

Click Here Today to Support Black Press and be a part of the Legacy!

Subscribe today for free and be the first to have news and information delivered directly to your inbox.

Select list(s) to subscribe to


By submitting this form, you are consenting to receive marketing emails from: Washington Informer Newspaper, 3117 Martin Luther King Jr. Ave SE, Washington, DC, 20032, http://www.washingtoninformer.com. You can revoke your consent to receive emails at any time by using the SafeUnsubscribe® link, found at the bottom of every email. Emails are serviced by Constant Contact
Close

Adblock Detected

Please consider supporting us by disabling your ad blocker